D. Vergidis

506 total citations
11 papers, 398 citations indexed

About

D. Vergidis is a scholar working on Genetics, Immunology and Molecular Biology. According to data from OpenAlex, D. Vergidis has authored 11 papers receiving a total of 398 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Genetics, 3 papers in Immunology and 2 papers in Molecular Biology. Recurrent topics in D. Vergidis's work include Immunotherapy and Immune Responses (2 papers), Cancer Genomics and Diagnostics (2 papers) and Clinical practice guidelines implementation (1 paper). D. Vergidis is often cited by papers focused on Immunotherapy and Immune Responses (2 papers), Cancer Genomics and Diagnostics (2 papers) and Clinical practice guidelines implementation (1 paper). D. Vergidis collaborates with scholars based in Canada and United States. D. Vergidis's co-authors include Charles Butts, Andrew W. Maksymiuk, Yvon Cormier, Mary A. Davis, Denis Soulières, Mary MacNeil, Ernie Marshall, Colum J Smith, Martin Palmer and Allan Price and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

D. Vergidis

11 papers receiving 384 citations

Peers

Countries citing papers authored by D. Vergidis

Since Specialization

Citations

This map shows the geographic impact of D. Vergidis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Vergidis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Vergidis more than expected).

Fields of papers citing papers by D. Vergidis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Vergidis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Vergidis. The network helps show where D. Vergidis may publish in the future.

Co-authorship network of co-authors of D. Vergidis

This figure shows the co-authorship network connecting the top 25 collaborators of D. Vergidis. A scholar is included among the top collaborators of D. Vergidis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Vergidis. D. Vergidis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	COVID Vaccination Rates in Children and Adults with Sickle Cell Disease in British Columbia, Canada 2021 ·Blood ·(unknown), (unknown), Lillian Ding, (unknown), Ali Amid, Caron Strahlendorf, (unknown), D. Vergidis, Maureen O’Donnell	3
2	Craniospinal irradiation in the treatment of chemotherapy refractory leptomeningeal metastasis from breast cancer: A case report 2021 ·Cancer Reports ·(unknown), D. Vergidis, (unknown)	1
3	Isolated CNS Blast Crisis of CML in A Patient on Dasatinib Therapy 2016 ·(unknown), D. Vergidis	2
4	Real-time clinical application of next-generation sequencing (NGS): Results from a multicenter program. 2013 ·Journal of Clinical Oncology ·Aaron R. Hansen, Andrew Brown, Philippe L. Bédard, Sébastien J. Hotte, Eric Winquist, Glenwood D. Goss, D. Vergidis, Hal W. Hirte, Stephen Welch, Tong Zhang, Lincoln Stein, Vincent Ferretti, Stuart Watt, Wei Jiao, Karen Ng, Teresa Petrocelli, Lillian L. Siu, John D. McPherson, Suzanne Kamel‐Reid, Janet Dancey	1
5	Antibody against Haemophilus influenzae protein D in patients with chronic conditions causing secondary immunodeficiency 2012 ·Vaccine ·(unknown), (unknown), William McCready, M L Brigden, S. Malik, D. Vergidis, (unknown), Marina Ulanova	11
6	Effectiveness of liposomal paclitaxel against MCF-7 breast cancer cells 2010 ·Canadian Journal of Physiology and Pharmacology ·(unknown), Misagh Alipour, D. Vergidis, Abdelwahab Omri, Clement Mugabe, John P.H. Th'ng, Zacharias E. Suntres	23
7	Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC) 2009 ·Journal of Clinical Oncology ·Charles Butts, H Anderson, Andrew W. Maksymiuk, D. Vergidis, Denis Soulières, Yvon Cormier, Mary A. Davis, E. Marshall, Martin Falk, Glen Goss	13
8	Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer 2005 ·Journal of Clinical Oncology ·Charles Butts, Nevin Murray, Andrew W. Maksymiuk, Glenwood Goss, Ernie Marshall, Denis Soulières, Yvon Cormier, Peter Ellis, Allan Price, Ravinder Sawhney, Mary A. Davis, Janine Mansi, Colum J Smith, D. Vergidis, Mary MacNeil, Martin Palmer	332
9	Chemopredictive diagnostic project in patients (pts) receiving capecitabine (X) or 5-FU/leucovorin (LV) as first-line chemotherapy for metastatic colorectal cancer (MCRC) 2004 ·Journal of Clinical Oncology ·Jean A. Maroun, Terence Moyana, (unknown), (unknown), (unknown), Derek J. Jonker, D. Vergidis, A. Wong	1
10	Knowledgeable, Consistent, Competent Care: Meeting the Challenges of Delivering Quality Cancer Care in Remote Northern Communities 2001 ·International Journal of Circumpolar Health ·Bruce Minore, (unknown), (unknown), D. Vergidis	6
11	Cytotoxic T cell response to minor histocompatibility antigens: apparent lack of H-2 restriction in killers stimulated by membrane fragments. 1982 ·The Journal of Experimental Medicine ·L M Pilarski, D. Vergidis	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact